###### Significance of this study

What is already known on this subject?
======================================

-   Genome-wide association studies have implicated numerous candidate genes for inflammatory bowel disease (IBD), but evidence of causality for specific variants is largely absent. Furthermore, by design, genome-wide association studies are limited to the study of common variants and overlook the functionally detrimental variation imposed by rare/novel mutation.

-   Exome analysis is fully informative for the spectrum of variation within the protein coding sequence of genes. It has been used to successfully identify disease causing variants in Mendelian disorders, but its potential to identify the missing heritability in complex diseases such as paediatric IBD has not yet been realised.

What are the new findings?
==========================

-   This study examines genetic variants from the perspective of the patient rather than the gene---for each paediatric case a profile of deleterious variation is determined across a comprehensive panel of known IBD genes.

-   Paediatric IBD patients carry a wide spectrum of low frequency variants within candidate IBD genes.

-   In silico analyses indicate a substantial proportion of these mutations are potentially deleterious.

-   Consistent with complex inheritance, this small subset of patients with severe IBD exhibit a varied profile of mutation with limited sharing of specific variants across the set of eight exomes.

###### Significance of this study

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Functional studies are required to confirm in silico assessment of variation impact on biology.

-   Even mutations confirmed to confer susceptibility must be considered among the full profile of disease predisposing variation present in any individual.

-   As the cost of next generation sequencing falls and the number of mutation profiles increases, there is clear potential for genetic characterisation of IBD phenotypic sub-types facilitating targeted therapeutic intervention/personalised medicine.

Introduction
============

Ulcerative colitis (UC) and Crohn\'s disease (CD) are the two main clinical phenotypes of inflammatory bowel disease (IBD), both resulting in chronic and relapsing inflammation. The incidence of IBD in the paediatric population of the UK is 5.2 per 100 000 children per year, with breakdown figures of 3.1 for CD, 1.4 for UC and 0.6 for IBD unclassified (IBDU).[@b1] While the precise aetiology and pathogenesis is complex and incompletely understood, it is widely accepted that IBD occurs as the result of a dysregulated mucosal immune response to commensal gut flora in the genetically susceptible host.[@b2] Familial aggregation of disease implies a strong genetic component,[@b3] although environmental factors may play a greater role in ulcerative colitis.[@b4]

Over recent years, genome-wide association studies (GWAS) have been applied with huge success to identify common genes involved in both CD and UC. Genes with replicated evidence for strong association suggest that pathways involving disruption of the innate and adaptive immune system, compromised epithelial barrier function and impaired autophagy play a significant role in disease.[@b2] However, despite the identification of over one hundred unique genes in IBD susceptibility, these common variants in combination account for less than a quarter of the genetic risk.[@b5; @b6; @b7] The source of this missing heritability is the subject of much debate with various explanations: overestimates of original heritability statistics; underpowered GWAS studies (in terms of sample size and single nucleotide polymorphism (SNP) coverage) to detect common variants associated with decreasing effect sizes; poorly investigated epistatic and gene--environment interactions; and rare variation.[@b8]

Rare variants form the group of infrequent mutations that occur in \<5% of the population. A large proportion of variants in this class occur at a much lower frequency (\<0.1%), and many thousands are likely to be specific to ethnic groups, isolates, families or even individuals. Nevertheless, this class of variation harbours multiple penetrant disease mutations conferring medium to high risk. Rare variants escape detection by GWAS. *BRCA1* and *BRCA2* are examples of familial breast cancer genes that harbour many high risk variants but go undetected by GWAS. This is consequent to each of the disease causing mutations being shared by only a fraction of the patient group and so no common SNP can act as a proxy or 'tag' to flag the gene as causal. It is entirely plausible that a proportion of IBD and other complex disease heritability unaccounted for by common variation lies within higher risk rare variants. Furthermore, many of these mutations may lie within genes already implicated by association studies.

Exome sequencing determines each letter of the genetic code at nearly all coding regions or exons in the genome (the 'exome'), thereby generating the complete profile of coding variation. It has already proved its success in identifying causal mutations in an ever growing list of both recessive and dominant rare Mendelian disorders whereby sequencing of a small number of unrelated cases has been used to identify disease causing variants.[@b9] One such case reported exome sequencing undertaken in a male child presenting at 15 months with intractable IBD; exome sequencing was used to successfully identify a causal mutation in the *XIAP* gene (X-linked inhibition of apoptosis gene) for which the child was hemizygous. After haematopoietic progenitor cell transplant treatment, as recommended for XIAP deficiency, the IBD resolved, suggesting that the Crohn\'s-like illness seen in this patient was driven by this single mutation.[@b10]

As next generation sequencing technology advances, it becomes increasingly affordable. Nevertheless, while costs remain in the region of several hundred pounds per sample, targeted analyses of those patient groups most likely to yield positive results is prudent. Prioritisation of cases with strong family history and/or patients representing the phenotypic 'extreme' of common traits is a useful strategy.[@b11] One such example of an 'extreme' phenotype is paediatric disease in which onset is particularly early. Genetic susceptibility is thought to play a more important role in the aetiology of early-onset IBD than in late-onset IBD.[@b12] This is supported by a higher rate of positive family history of IBD in patients with a younger age at diagnosis compared to the older age group, suggesting that an earlier presentation may be due to a higher burden of disease-causing mutations in the genomes of these affected children compared to those in whom disease manifests later in life.[@b13] In addition, environmental confounding factors such as smoking are less likely to be exerting an influence on disease in paediatric cohorts. It has also been suggested that early-onset disease may in itself be a more aggressive phenotype; in CD, earlier age at diagnosis is associated with a greater need for surgery and increased small bowel disease.[@b12; @b13; @b14]

Two of the most comprehensive association studies investigating IBD have used adult cohorts, but a recent GWAS of 3246 early-onset IBD cases successfully identified five new loci associated with childhood susceptibility as well as replicating loci previously implicated in adult-onset disease.[@b15] Early-onset disease genes have also been located using linkage analysis and candidate gene sequencing approaches undertaken in two unrelated consanguineous families.[@b16] Despite distinct clinical and histopathological features of the CD and UC phenotypes, an estimated 30% of IBD-related loci are shared between both phenotypes.[@b2] It is likely that further study of rare variation across implicated genes may uncover more commonality.

The application of exome sequencing to complex diseases is fraught with analytical difficulty; finding disease causing variants among the many innocent variants present in the genome has been likened to finding 'needles in stacks of needles'.[@b17] Targeting analyses to subsets of genes in patients with extreme phenotype is a practical approach to examining genetic influence in disease. In this study we apply next generation sequence technology to paediatric IBD (PIBD). The study is focused on a small cohort of eight paediatric patients with markedly early onset/severe disease. Patients are representative of the spectrum of IBD presentation, and limiting the study to this modest number makes data interpretable on a case-by-case basis. We focus on a comprehensive panel of known causal genes and for each patient describe their individual burden of rare and novel damaging variation.

Materials and methods
=====================

Recruitment of paediatric IBD cohort of patients
------------------------------------------------

Children included in this study were selected from the 'Genetics of Paediatric IBD' cohort between October 2010 and October 2011. This cohort was recruited through tertiary referral paediatric IBD clinics at the University Hospital Southampton Foundation Trust. This hospital is the regional centre for paediatric gastroenterology, providing a tertiary paediatric gastroenterology and endoscopy service for the Wessex region, and draws on a patient population of 3.5 million. The service has a rolling database of over 300 paediatric IBD cases and approximately 50--70 patients are diagnosed each year. All children had a diagnosis of IBD and were aged between 5 and 18 years at time of recruitment, although their diagnosis may have been made at an earlier age. Diagnosis was established using the Porto criteria[@b18]; all children had compatible history, examination and laboratory investigation results, and infectious causes excluded. All were investigated with upper gastrointestinal endoscopy and ileo-colonoscopy. Written informed consent was obtained from the attending parent of all children, and the child where appropriate. In the initial recruitment interview, clinical data and venous blood samples (10 ml for DNA extraction and 8 ml for plasma extraction) were collected. Additional comprehensive clinical data were extracted from patient records. For each patient we gathered information on gender, dates of birth and initial diagnosis, disease extent currently and at diagnosis using the Paris classification,[@b19] disease activity score at diagnosis (using the paediatric CD activity index (PCDAI) and the paediatric ulcerative colitis activity index (PUCAI)), height and weight currently and at first diagnosis, time to and date of first relapse, treatment history (use of steroids, immunomodulators, biological therapies, surgery), history of potential aetiological and modifying conditions such as smoking, gastrointestinal infection and other autoimmune disease, and family history.

Ethics statement
----------------

This study was approved by the Southampton and South West Hampshire Research Ethics Committee (REC) (09/H0504/125) and University Hospital Southampton Foundation Trust Research & Development (RHM CHI0497).

Selection of samples
--------------------

Eight patient samples from our PIBD cohort as previously described were selected for exome sequencing for this study. These eight patients were selected based on age of diagnosis, disease severity or positive family history in a first degree relative. Selection criteria and patient phenotypic characteristics are summarised in [table 1](#tbl1){ref-type="table"}.

###### 

Summary of patient phenotypes and characteristics (specific selection criteria are in bold)

  Sample ID   Age at diagnosis (years)   Sex      Disease   Phenotype description and selection criteria                                                                                           Ethnicity       Family history
  ----------- -------------------------- -------- --------- -------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------
  Proband 1   11                         Male     CD        **Severe disease requiring surgery**/ Stricturing ileo-colonic disease requiring right hemicolectomy within 6 months of diagnosis.     White British   --
  Proband 2   7                          Female   CD        **Early age of onset**/non-stricturing, non-penetrating mild to moderate pancolitis, disease resistant to treatment.                   White British   --
  Proband 3   6                          Male     CD        **Early age of onset**/non-stricturing, non-penetrating granulomatous colitis and duodenitis. **Mother diagnosed CD aged 21 years**.   White British   \+
  Proband 4   6                          Female   CD        **Early age of onset**/non-penetrating pancolitis with possible ileo-caecal stricture.                                                 White British   --
  Proband 5   13                         Male     CD        Non-stricturing, non-penetrating, colitis. **Family history** including maternal CD and maternal grandparental UC.                     White British   \+
  Proband 6   9                          Male     UC        **Severe** left sided colitis, also with oral pemphigus.                                                                               White British   --
  Proband 7   2                          Male     UC        **Early age of onset**/mild to moderate pancolitis.                                                                                    White British   --
  Proband 8   3.5                        Male     IBDU      **Early age of onset**/left sided colitis.                                                                                             Iraqi           --

CD, Crohn\'s disease; IBDU, inflammatory bowel disease unclassified; UC, ulcerative colitis.

DNA and plasma extraction
-------------------------

Genomic DNA was extracted from EDTA anticoagulated peripheral venous blood samples using the salting out method. Plasma was isolated from lithium--heparin anticoagulated peripheral venous blood samples using standard methods.

Exome sequencing
----------------

Targeted exome capture was performed using the SureSelect Human All Exon 50Mb kit (Agilent). The Illumina HiSeq system was used to generate sequence data. These steps were conducted at the Wellcome Trust Centre for Human Genetics at Oxford University. The resultant paired end sequencing data were aligned against the human genome reference sequence 18 (hg18) using the Novoalign software (2.06.09MT, Novocraft Technologies, Selangor, Malaysia). Duplicate reads, resulting from PCR clonality or optical duplicates, and reads mapping to multiple locations were excluded from downstream analysis. Depth and breadth of sequence coverage was calculated with custom scripts and the BedTools package.[@b20] Single nucleotide substitutions and small insertion deletions were identified and quality filtered within the SamTools software package[@b21] and in-house software tools. Variants were annotated with respect to genes and transcripts with the Annovar tool.[@b22] Summary statistics for exome sequencing, mapping and coverage are shown in supplementary table 1 (available online only). Data from the 1000 Genomes Project (1KG) phase I (2010 November release) were utilised using LiftOver (University of California Santa Cruz Genome Browser, <http://genome.ucsc.edu/cgi-bin/hgLiftOver>) for the conversion of 2010 November coordinates to hg18. Variants were characterised as novel if they were previously unreported in the dbSNP129, dbSNP132, 1KG data and our 22 in-house reference exomes (supplementary table 2). Southampton reference exomes for evaluating the burden of mutation comprised independent DNA samples from unrelated individuals who were exome sequenced on the same platform at the same time as part of other local projects. Each reference exome was from a patient with a distinct clinical diagnosis but no history of gastrointestinal or autoimmune disease. The clinical phenotypes of the 22 reference exomes included 10 with leukaemia, 5 with lymphoma, 4 with Beckwith--Wiedemann syndrome and 3 with macrocephaly malformation syndrome.

The National Heart Lung and Blood Institute Exome Sequencing Project Exome Variant Server (<http://evs.gs.washington.edu/EVS/>) (Feb 2012) was used as a reference dataset for rare variant allele frequency in a European American population ([table 2](#tbl2){ref-type="table"}). This project contains exome data from approximately 3500 European American individuals taken from 12 disease cohorts with a range of heart, lung or blood disorders.

###### 

Characterisation of non-synonymous, stopgain and indel variants with an alternative allele frequency of \<0.05 or not reported in 1000 genomes across 39 known IBD genes

  --
  --

Novel variants are shown in grey.

Where a specific variant is present in a proband, this is indicated by a dot (.).

Where a specific variant is present in a proband and has a SIFT score of \<0.05 this is indicated by a ◊.

\*Indicates the first bp location of a 3-bp deletion.

†Indicates a dinucleotide variant (that for *IL18RAP* results in a codon change from CTG\>AAG, resulting in p.L428K amino acid change).

‡NR indicates variants that despite not being reported in dbSNP132 or 1000 genomes, are reported in dbSNP129 or seen in our in-house reference exomes and are therefore not characterised as novel.

B, benign; C, conservative; fi, frameshift insertion; MC, moderately conservative; MR, moderately radical; nd, non-frameshift deletion; NR, not reported; ns, non-synonymous; PoD, possibly damaging; PrD, probably damaging; R, radical; sg, stopgain; U, unknown.

Selection of a panel of known IBD genes
---------------------------------------

We constructed a panel of high priority genes previously shown to be strongly associated with IBD. Our aim was to include all genes with convincing evidence for disease causality in previous studies. Selection was based on the findings of two genome-wide meta-analyses of IBD,[@b5] [@b6] one genome-wide association study of early-onset IBD,[@b15] and one linkage study in consanguineous families with early-onset IBD.[@b16] Gene names were cross referenced with the Human Genome Nomenclature Committee to ensure that the most up-to-date versions of gene names were applied (<http://www.genenames.org/>). Our consolidated panel represented 169 genes (supplementary table 3).

Evaluation of spectrum of mutation and predicted functional impact
------------------------------------------------------------------

Exome data from our eight patients were cross-referenced against our gene panel described above. Synonymous variants were excluded from analysis due to their decreased likelihood of functional effect on protein. SIFT ('sorting intolerant from tolerant') scores[@b23] were annotated using Annovar, or where scores were missing, were derived indirectly using the database of non-synonymous functional prediction.[@b24] A small number of additional missing scores were obtained from the SIFT server at <http://sift.jcvi.org>. SIFT is a sequence homology-based tool that predicts whether an amino acid substitution is likely to affect protein function. Variants with SIFT scores of \<0.05 are considered 'deleterious', and SIFT therefore allows prioritisation of amino acid changes by ranking according to score.

We examined in silico predictions from the Polyphen2 (Polymorphism Phenotyping v2) server at <http://genetics.bwh.harvard.edu/pph2/bgi.shtml>.[@b25] Polyphen2 uses a probability model to generate thresholds and classify polymorphisms as benign, possibly damaging or probably damaging, based on 11 predictive features relating to sequence, phylogenetic and structural information which characterise the substitution. Additional functional predictions of the result of each amino acid change were derived from Grantham scores,[@b26] which predict the effect of amino acid substitutions according to chemical properties including polarity and molecular volume. The Grantham distance, d, between two amino acids is classified as conservative (0\<d≤50), moderately conservative (50\<d≤100), moderately radical (100\<d≤150) or radical (d\>150).[@b27] Radical changes predicted by these scores are linked to clinical phenotypes.[@b28]

Burden of mutation
------------------

Using only novel variants or variants with an alternative allele frequency of \<0.05 in the 1000 genomes data, a χ^2^ contingency test was performed to test for an excess of rare potentially deleterious variants (non-synonymous and frameshift indels) compared to neutral synonymous variants, within the panel of known IBD genes in our eight cases compared to 22 reference exome samples from non-IBD patients.

Results
=======

Exome sequencing
----------------

On average, each PIBD exome had 78% of mappable bases of the Gencode defined exome represented by coverage of at least 20 reads (supplementary table 1). For each patient approximately 23 000 variants were found. After exclusion of synonymous variants, approaching 13 000 variants were found per patient, of which approximately 300 were novel (supplementary table 2).

Characterisation of mutations in genes known to be associated with IBD
----------------------------------------------------------------------

Across all eight exomes, we found 332 variants (excluding synonymous) among 104 of our panel of 169 genes (supplementary table 4). Of these, approximately 40% (122) were found in HLA class genes. Seventeen were novel variants not previously reported in public databases or our own in-house database of non-IBD patient reference exomes.

[Table 2](#tbl2){ref-type="table"} describes the set of variants remaining after removal of splicing, common (where the alternative allele frequency in 1000 genomes is reported as \>0.05) and *HLA* variants. Fifty-eight variants within 39 genes remain, of which 17 are novel.

The χ^2^ analysis to test for an excess of deleterious rare variants in known and candidate IBD genes in IBD cases listed in [table 2](#tbl2){ref-type="table"} compared to 22 reference exomes did not reach statistical significance (supplementary table 5).

Crohn\'s disease patient profiles
---------------------------------

Only two patients with early onset CD exhibit rare potentially deleterious variations within *NOD2*.

Proband 1 was diagnosed with CD aged 11 years and required a right hemicolectomy for extensive ileo-caecal stricturing. He is a heterozygote carrier of the *NOD2* R702W variant that is associated with a twofold increase in odds ratio of CD.[@b29] In addition he harbours potentially damaging mutations in *GSDMB* and *ZNF365* and a dinucleotide variant of undetermined functionality on one chromosomal copy of the *IL18RAP* gene. The presence of ileal disease and a stenotic phenotype in this patient is also consistent with his *NOD2* variant profile.[@b29]

Proband 2 carries a novel variant in each of the *SEC16A* and *SH2B1* genes. This patient also has a rare variant in *JAK2*; however, SIFT scoring suggests none of these mutations are likely to be particularly deleterious.

Proband 3 is the second patient with *NOD2* variation and carries both the R702W variant and the L1007 frameshift insertion. Carriage of two or more high risk alleles in *NOD2* confers a 17-fold increased risk of IBD.[@b29] Exome analysis cannot determine if both variants have been co-inherited on the same chromosome. Proband 3 additionally possesses potentially deleterious variants in *ERAP2* and *SEC16A*.

Proband 4 presented with severe disease aged 6 years. She carries the *NOD2* V955I variant, but this is predicted to be innocuous as is her private variant in *KIF21B*. She is a heterozygote for a number of previously seen variants with borderline (∼0.05) SIFT scores (*FUT2*, *MTMR3*). The most distinct rare (frequency of 0.003) and potentially deleterious variant observed in this patient is the A928V variant in the *TYK2* gene.

Proband 5 possesses one variant in the *GMPBB* gene and another in *HORMAD2*, both estimated by SIFT to be harmful. The former is ascertained as novel to this individual, whereas the latter occurs in \<0.5% of chromosomes studied in the thousand genomes project, but in just over 1% of the 3500 exomes tested in Exome Variant Server.

UC and IBDU patient profiles
----------------------------

Proband 6 has a histological diagnosis of UC and carries novel deleterious mutations in the *BACH2*, *C1orf93* and *SEC16A* genes. A fourth novel variant in the *IL10* gene also has a low SIFT score.

Proband 7 is a boy, diagnosed aged 2, and similar to our other UC patient, exhibits a potentially functionally detrimental mutation in *BACH2* and a second very rare and possibly damaging mutation in *IL10*. The *IL1RL2* and *SNAPC4* genes are also apparently compromised in this individual.

Proband 8 was diagnosed at a young age with IBDU, and possesses two possibly harmful variants in *ICAM1*, one in *BTNL2* and a novel deleterious variant in *SH2B1*.

Predicted functional impact
---------------------------

[Figure 1](#fig1){ref-type="fig"} illustrates relationships between SIFT, Grantham and Polyphen2 scores for all non-synonymous variants in [table 2](#tbl2){ref-type="table"}. There is particularly close agreement between SIFT and Polyphen2 scores as noted previously.[@b30] Agreement with Grantham scores is less clear, but there is striking concordance between the vast majority of variants with a SIFT score \>0.2 (benign) being independently designated benign by Polyphen2 and conservative by Grantham. Notably, two variants are classified as radical by Grantham and probably damaging by SIFT and/or Polyphen2---*CXCR1* (R335C) and *ICAM1* (R367C)---with the latter being classified as radical/damaging by all three criteria.

![In silico functional predictions.](gutjnl-2011-301833f01){#fig1}

Discussion
==========

In this study we have applied exome sequencing, which allows the screening of the complete spectrum of variation within protein coding genes. There is abundant evidence that such regions are likely to be highly enriched for disease causing variation.[@b31] We have focused on the identification of rare and novel variation within genes known to contain causal variants or identified as candidate genes for IBD. Excluding *HLA* variants and considering only rare non-synonymous, stop-gain mutations and indels, we uncovered 58 variants across 39 genes, of which 17 were not previously reported. Of these, 35% (20 variants) have SIFT scores under 0.05, 12 of these are also classified as probably damaging by Polyphen2 and five of these (*BTNL2*: S334L; *C1orf93*: G176R; *ICAM1*: R367C; *NOD2*: R702W and *SH2B1*: L185Q) are also classified as moderately radical or radical by Grantham score. One variant, *CXCR1* (R335C), has a borderline SIFT score of 0.09 and is classified as probably damaging by Polyphen2 and radical by Grantham score. These variants may compromise protein function and contribute to the PIBD phenotype in these patients.

Our study included five patients with childhood onset CD. The variant profiles show that four of these patients carry potentially deleterious mutations in one or more IBD candidate genes. One child had a 17-fold increased risk of IBD on the basis of his *NOD2* profile alone. Others in this group bear variants with likely impact on antigen presentation (*ERAP2*), endoplasmic reticulum trafficking (*SEC16A*) and T-helper cell differentiation. A variant in the *IL18RAP* gene was recently reported by Rivas *et al* [@b7] to carry a threefold OR for CD, and variants in the same gene have also been implicated in coeliac disease.[@b32] We identify a rare, non-synonymous, two-base pair mutation in this gene in one of our severely affected early onset CD cases. Our study examined only two patients with a clear diagnosis of UC and intriguingly we observe unique, potentially deleterious variation in both the B-cell regulatory gene *BACH2* and *IL10* genes in both patients. Interestingly, defective *IL10* functioning is already recognised in UC pathogenesis,[@b33] [@b34] whereas although other components of B-cell signalling (*IL7R* and *IRF5*) have shown previous association with UC,[@b6] variation in *BACH2* has shown previous association with CD only. Our patient with undetermined IBD is the only patient with rare *ICAM1* variants. This gene, in which our IBDU patient carries two functionally damaging variants, plays a role in cell-mediated inflammation and has been identified as a therapeutic target in IBD.[@b35]

Assessing our results obtained for each individual in our cohort with IBD, we can see clearly that it is possible to generate an individualised variant profile for each patient. Individualised profiles are already being usefully applied to refine disease diagnosis. For example, Franke *et al* [@b36] reported recently on a whole genome sequencing undertaken on a 47-year-old patient diagnosed with CD in her 20s. Her case was particularly severe, as she had failed standard treatments including anti-TNF, had undergone multiple bowel resections, and required intermittent parenteral nutrition. Sequencing in this patient revealed multiple 'hits' in the autophagy pathways. This prompted in-depth mycobacterial diagnostics and ultimately resulted in a diagnosis of chronic active *Mycobacterium avium* infection.

Although suggestive and interesting mutation profiles have emerged from our small panel, it is clear that our picture is far from complete. Proband 3 displays rare variation across many genes, but not one of these appears to have potential functional consequence. Furthermore, in 65 genes previously linked to IBD, we identified no variants in our eight probands. It is possible that these genes do not contribute to disease in this small group, consistent with a high degree of genetic heterogeneity in this complex disease. It is also possible that limitations of sequencing technology or the analytical pipeline could have resulted in failure to call true variants. By focusing our analysis on exomes, we rely on the fact that many of the non-coding SNP variants previously implicated by GWAS simply flag coding variants in the genomic vicinity. Protein-coding genes harbour about 85% of the mutations with large effects for disease-related traits,[@b37] but it is entirely possible that restriction of the exome capture to coding regions might have overlooked non-coding variants with significant impact on protein expression. By tabulating rare and novel variants, we are focusing attention on those variants hypothesised to have larger effect sizes on the assumption that such variants confer significant genetic contribution to childhood severe and/familial disease.[@b38] However, for any complex disease, multiple common susceptibility variants, each contributing very modest effect sizes, should not be ignored.

SIFT, Polyphen2 and Grantham scores provide an indication of potential causality but they must be interpreted with caution, particularly for complex traits. Kumar *et al* [@b39] describe in silico prediction such as SIFT as effective for monogenic disease, but consider such tools to be less effective for lower penetrance variants associated with complex diseases. Furthermore, one study compiled in silico prediction scores and found pairwise agreement between all methods to be in the range 60--70%, implying fairly substantial disagreement.[@b24] These and other studies underpin the difficulty in ascribing functional evidence and translational importance of genetic variants, and the particular difficulty in heterogeneous complex disease. However, it is notable that published evidence demonstrates a clear functional impact for two of the six variants listed above as having an overall deleterious score by two or more of the in silico measures. The *CXCR1* gene R335C variant has been previously implicated in chronic obstructive pulmonary disease and asthma.[@b40] The two *CXCR1* mutations listed in [table 2](#tbl2){ref-type="table"} (R335C and M31R) are in tight linkage disequilibrium and both are known to alter the structure and charge of the protein at the respective positions. The N-terminus of CXCR1 protein has been identified as potentially important for receptor--ligand binding, leading to the suggestion that the M31R variant may affect this interaction. This led to the hypothesis that both polymorphisms could impact receptor function through alterations in structure.[@b41] The upper right quadrant of [figure 1](#fig1){ref-type="fig"} indicates those variants where all three *in silico* prediction tools are concordant in ascribing detrimental effects of the variant. Mutations such as the rare R376C *ICAM1* variant may modify the function of the encoded glycoprotein expressed on immune and endothelial cells and should be prioritised for functional assessment. Another non-synonymous variant highlighted by the in silico scores is the *NOD2* R702W variant which, together with the *NOD2* L1007fs variant, has been found to impair the activation of the NF-κB pathway in response to muramyl dipeptide (MDP), a bacterial wall component, with the L1007fs mutant unable to respond.[@b42] NOD2 is localised to the cell membrane but the L1007fs polymorphism disrupts this association and thus the protein has cytoplasmic distribution. Forcing the L1007fs mutant protein to associate with the plasma membrane does not lead to activation of the NF-κB pathway in response to MDP; thus it is not the localisation of the NOD2 mutant, but rather an inability to respond to MDP, that affects induction of the NF-κB pathway. The L1007fs mutation has been shown to produce a truncated protein with impaired function.[@b43] The *NOD2* R702W variant occurred in four of the 22 non-IBD reference exomes, representing a higher than expected frequency. Although the reference exomes were composed of germline DNA from patients with diverse diagnoses (various lymphomas, leukaemias and congenital growth disorders), all four of these IBD negative controls had a diagnosis of chronic lymphocytic leukaemia. Interestingly, a population based cohort study of 47 679 Swedish patients with CD or UC, reported a 20% increased risk of haematopoietic cancers in these patients.[@b44] However, the role of *NOD2* polymorphisms has been further investigated in a variety of cancers, with most finding no association.[@b45] Recently, however, Sivakumaran *et al* [@b46] found abundant evidence for pleiotropy in complex disease, defined as one gene having an effect on multiple phenotypes. The authors identified many genes harbouring variants associated with CD and other immune-mediated phenotypes. These associations include a CD association with chronic lymphocytic leukaemia, through the *SP140* gene (within which a rare variant is listed in [table 2](#tbl2){ref-type="table"}). Other gene/disease associations linked with CD include *BACH2* with type 1 diabetes and coeliac disease, *IL18RAP* in coeliac disease, *IL1RL1* with eosinophil count and coeliac disease, *MST1* with UC and primary sclerosing cholangitis, *ZNF365* with breast cancer, and *NOD2* with leprosy, among many others.[@b47] All of these genes contain rare variants listed in [table 2](#tbl2){ref-type="table"} within the eight patients we have exome sequenced.

The abundance of potentially damaging variants arising from next generation sequencing renders interpretation of the potential impact of disease challenging. However, focusing on early onset and other forms of 'severe' phenotype, including familial cases, coupled with our ability to filter variants identified with increasingly large and reliable databases of apparently neutral variants, offers the prospect of identifying important rare variants involved in complex traits such as IBD. This is the first study whereby a cohort of patients have been exome sequenced with the specific aim of generating a unique and personalised profile of rare variants across known disease genes for each patient. The rare variant profiles presented here provide a relatively small number of potential causal variants and include many mutations classed as deleterious by in silico prediction, a number of potential compound heterozygotes and a number of variants for which there is established functional evidence of roles in disease. These data, assessed from the perspective of individual patients, provide one of the first glimpses of personal mutation profiles and establish a foundation to elucidate the disease significance of these variants in future next-generation sequencing analyses of PIBD patients.
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======================
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